Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

benzinga.com/news/fda/25/07/46365547/capricors-lead-duchenne-therapy-hits-fda-regulatory-roadblock

Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday.
The company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for Deramiocel, the company’s lead cell therapy candidate…

This story appeared on benzinga.com, 2025-07-11 13:03:38.
The Entire Business World on a Single Page. Free to Use →